Aptinyx slides as diabetic pain trial fails to reach main goal

seekingalpha2022-04-07

syahrir maulana/iStock via Getty Images The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

不油腻的哒哒哒
2022-04-07
不油腻的哒哒哒
failure is the mother of success

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2225263513?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-04-07 21:31","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2225263513","market":"us","top_or_hot":-1,"title":"Aptinyx slides as diabetic pain trial fails to reach main goal","media":"seekingalpha","content":"<div>\n<p>syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptinyx slides as diabetic pain trial fails to reach main goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptinyx slides as diabetic pain trial fails to reach main goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 21:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal","article_id":"2225263513","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2225263513","pubTimestamp":1649338269,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APTX":"Aptinyx Inc."},"translate_title":"Aptinyx幻灯片作为糖尿病疼痛试验未能达到主要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APTX":1},"content_text":"syahrir maulana/iStock via Getty Images   The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN).  The 229-patient randomized, double-blind study did not demonstrate a statistically significant separation from placebo in terms of its primary endpoint, which was the change in pain from baseline measured over 12 weeks using a rating scale, the company said. “We are clearly disappointed that the study did not meet its primary endpoint,” Chief Executive Andy Kidd remarked, adding, “unfortunately, the data from this study do not currently point to a path forward in development for painful DPN.” However, the experimental therapy was well tolerated in the trial with no “concerning safety issues.” according to Aptinyx (APTX). NYX-2925 is currently undergoing a Phase 2b study for fibromyalgia, with data expected in mid-3Q 2022, the company said.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":619521606,"gmtCreate":1649341811621,"gmtModify":1649341811621,"author":{"id":"4094711751257690","authorId":"4094711751257690","name":"不油腻的哒哒哒","avatar":"https://static.tigerbbs.com/521e89acc5ee91cd53fceb36809286c3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4094711751257690","authorIdStr":"4094711751257690"},"htmlText":"failure is the mother of success","listText":"failure is the mother of success","text":"failure is the mother of success","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/619521606","repostId":2225263513,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2225263513"}